GlassScriptPhysician profile
Vincent M Sottile
NPI 1790765493
$2,758.09
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $638 · 2021: $615 · 2022: $38.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $680.59 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $328.83 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $138.31 | 2019-2021 | |
| Janssen Biotech, INC. | $133.18 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $129.13 | 2019 | |
| Ironwood Pharmaceuticals, INC | $123.67 | 2019-2021 | |
| Braintree Laboratories, INC. | $92.13 | 2019-2021 | |
| Shionogi INC | $83.45 | 2019 | |
| Nestle Healthcare Nutrition INC. | $73.00 | 2021 | |
| Redhill Biopharma INC. | $72.12 | 2020-2021 | |
| Celgene Corporation | $70.24 | 2021 | |
| Pfizer INC. | $69.61 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $67.80 | 2019-2021 | |
| Gilead Sciences, INC. | $51.71 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $40.00 | 2021 | |
| Alfasigma USA, INC. | $31.65 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $25.42 | 2019 | |
| Olympus America INC. | $24.91 | 2022 | |
| Evoke Pharma, INC. | $22.63 | 2021 | |
| Romark Laboratories, Lc | $21.64 | 2020 | |
| Vivus LLC | $17.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.21 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Sottile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.